The share acquisitions announced by Orion Corporation on 25 August 2022 have been completed. The Company has purchased during the time period from 1 September 2022 to 4 November 2022 through trading on regulated market organised by Nasdaq Helsinki Oy a total of 400,000 Company's own B shares at an average price per share of approximately EUR 44.7956. The total purchase price paid for the shares was EUR 17,918,232.27.
After the repurchases, the Company holds a total of 932,771 own B shares corresponding to approximately 0.66% of the total number of the shares and 0.12% of the votes.
| Liisa Hurme|
President and CEO
| Olli Huotari|
SVP, Corporate Functions
Olli Huotari, SVP, Corporate Functions, tel. +358 10 426 3054
Orion is a globally operating Finnish pharmaceutical company – a builder of well-being. Orion develops, manufactures and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients. The company is continuously developing new drugs and treatment methods. The core therapy areas of Orion’s pharmaceutical R&D are oncology and pain. Orion’s net sales in 2021 amounted to EUR 1,041 million and the company had about 3,350 employees at the end of the year. Orion’s A and B shares are listed on Nasdaq Helsinki.